- Home
- DSGN vs TVGN Comparison
DSGN vs TVGN Comparison
Compare DSGN & TVGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSGN
- TVGN
- Stock Information
- Founded
- DSGN 2017
- TVGN 2020
- Country
- DSGN United States
- TVGN United States
- Employees
- DSGN N/A
- TVGN N/A
- Industry
- DSGN Biotechnology: Pharmaceutical Preparations
- TVGN Blank Checks
- Sector
- DSGN Health Care
- TVGN Finance
- Exchange
- DSGN Nasdaq
- TVGN Nasdaq
- Market Cap
- DSGN 208.9M
- TVGN 193.1M
- IPO Year
- DSGN 2021
- TVGN N/A
- Fundamental
- Price
- DSGN $3.77
- TVGN $1.24
- Analyst Decision
- DSGN Hold
- TVGN Strong Buy
- Analyst Count
- DSGN 1
- TVGN 1
- Target Price
- DSGN $4.00
- TVGN $10.00
- AVG Volume (30 Days)
- DSGN 82.2K
- TVGN 727.8K
- Earning Date
- DSGN 08-04-2025
- TVGN 08-13-2025
- Dividend Yield
- DSGN N/A
- TVGN N/A
- EPS Growth
- DSGN N/A
- TVGN N/A
- EPS
- DSGN N/A
- TVGN N/A
- Revenue
- DSGN N/A
- TVGN N/A
- Revenue This Year
- DSGN N/A
- TVGN N/A
- Revenue Next Year
- DSGN N/A
- TVGN N/A
- P/E Ratio
- DSGN N/A
- TVGN N/A
- Revenue Growth
- DSGN N/A
- TVGN N/A
- 52 Week Low
- DSGN $2.60
- TVGN $0.26
- 52 Week High
- DSGN $7.77
- TVGN $3.09
- Technical
- Relative Strength Index (RSI)
- DSGN 49.66
- TVGN 51.33
- Support Level
- DSGN $3.33
- TVGN $1.20
- Resistance Level
- DSGN $4.21
- TVGN $1.27
- Average True Range (ATR)
- DSGN 0.24
- TVGN 0.06
- MACD
- DSGN -0.02
- TVGN -0.00
- Stochastic Oscillator
- DSGN 50.29
- TVGN 55.88
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.
About TVGN Tevogen Bio Holdings Inc. Common Stock
Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs or CTLs), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders.